Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome

Abstract

Background: The metabolic syndrome is associated with an increased risk of cardiovascular complications. Especially patients with evident cardiac pathology are at high risk for further complications. A sufficient weight reduction would improve the metabolic pathology and reduce the cardiovascular risk. Unfortunately, overweight and obese patients, even with complicated coronary heart disease, do not alter lifestyles regarding fat intake and physical activity, and in a quarter of these patients body weight increases in the follow-up period. Nonetheless, these patients need a weight reduction to be protected from further cardiovascular complications. Therefore, in overweight patients with insulin resistance in whom lifestyle recommendations have failed, orlistat has been used as an adjunct to decrease significantly overweight and to improve the metabolic pathology without increasing mortality. In our opinion, orlistat could also be an adjunct to lifestyle changes in adipose, diabetic patients with the metabolic syndrome and established heart pathology and signs of incipient cardiac dysfunction. Furthermore, we hypothesize that following a sufficient weight reduction improvements in metabolic pathology and, more important to us, in cardiac dysfunction should be observed. Methods: We selected 90 adipose patients with the metabolic syndrome, diabetes type 2, hypertension, mostly with coronary heart disease and concomitant cardiac dysfunction. Cardiac dysfunction was stated when the amplitude of dyspnea was greater than class 2 of the New York Heart Association (NYHA) and when resting left ventricular ejection fraction (LVEF) was <50%. Patients attended standardized nutritional counseling sessions. The caloric restriction was sufficient to create a deficit of 500 calories per day with <30% of total calories derived from fat. All patients were also enrolled in a standardized physical program and were also encouraged to walk briskly for at least 30 min per day. Patients were divided into two groups. Orlistat (120 mg t.i.d.) and placebo (1 capsule t.i.d.) were administered according to a double-blind protocol. Results: Baseline pathology was similar in the two groups, with the exception of hemoglobin (Hb) A1C, which was slightly higher in the orlistat group, the difference being statistically significant (p = 0.031). Unfortunately, lifestyle changes (diet and exercise) induced only small changes with respect to overweight in the placebo group (no orlistat). The metabolic pathology and the cardiac dysfunction did not improve. As expected, in the other group treated with orlistat in addition to lifestyle changes, weight and body mass index decreased significantly (p < 0.001 and p = 0.013, respectively). In parallel the metabolic pathology, especially dyslipidemia, was significantly reduced. Total cholesterol, LDL cholesterol, and triglycerides decreased, while HDL cholesterol increased. These changes were very significant (p < 0.001, p = 0.001, p = 0.001 and p < 0.001, respectively). Uricemia decreased slightly (p = 0.043)...

Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials

“…Our finding of the effect of orlistat on SUA level improvement was supported by evidence from previous trials 20,21 and in the first group of one trial. 25 However, in contrast to our results, some trials revealed that orlistat is caused decrease SUA but not significantly 22,24 and in the first group of one trial. 26 Also one trial 23 and in the second group of two trials 25,26 were showed that increase SUA after orlistat therapy.…”

Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients<subtitle>Systematic Review and Meta-analysis</subtitle>

“…Of the 4 studies investigating sibutramine, 3 53,55,56 found that heart rate increased in patients treated with sibutramine and decreased or did not change in the control groups. Only 1 study 52 showed lowering of heart rate in the intervention and control groups, with a 49 Cocco et al, 50 more pronounced decrease in patients with sibutramine therapy.…”

Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes

“…Eighteen of the studies were randomized controlled trials of mainly dietary interventions . There were 30 randomized, placebo‐controlled trials of obesity drugs, including orlistat, cetilistat, sibutramine, topiramate, rimonabant, taranabant, CP‐945,598, and lorcaserin . All but one of the drug trials included the dietary advice of reduced energy intake in all treatment groups.…”